Literature DB >> 19584672

Intravenous immunoglobulin a natural regulator of immunity and inflammation.

Stanley C Jordan1, Mieko Toyoda, Ashley A Vo.   

Abstract

Intravenous immunoglobulin (IVIG) products are derived from pooled human plasma and have been used for the treatment of primary immunodeficiency disorders for more than 25 years. IVIG products are also effective in the treatment of autoimmune and inflammatory disorders; however, the precise mechanism(s) of action is not known. Recent investigations suggest that IVIG has a much broader ability to regulate cellular immunity including innate and adaptive components. IVIG is also a recently recognized modifier of complement activation and injury. Here, we discuss these important advancements and how this knowledge applies to desensitization protocols and to the treatment of antibody-mediated rejection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19584672     DOI: 10.1097/TP.0b013e3181a9e89a

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  28 in total

Review 1.  Immunotherapy of systemic sclerosis.

Authors:  Rebecca Manno; Francesco Boin
Journal:  Immunotherapy       Date:  2010-11       Impact factor: 4.196

2.  Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils.

Authors:  Ian K Campbell; Sylvia Miescher; Donald R Branch; Patrick J Mott; Alan H Lazarus; Dongji Han; Eugene Maraskovsky; Adrian W Zuercher; Anton Neschadim; Danila Leontyev; Brent S McKenzie; Fabian Käsermann
Journal:  J Immunol       Date:  2014-04-23       Impact factor: 5.422

Review 3.  Treatment options and strategies for antibody mediated rejection after renal transplantation.

Authors:  Matthew H Levine; Peter L Abt
Journal:  Semin Immunol       Date:  2011-09-21       Impact factor: 11.130

4.  Low incidence of acute rejection in hepatitis B virus positive liver transplant recipients and the impact of hepatitis B immunoglobulin.

Authors:  Annapoorani Veerappan; Lisa B VanWagner; James M Mathew; Xuemei Huang; Joshua Miller; Brittany Lapin; Josh Levitsky
Journal:  Hum Immunol       Date:  2016-02-23       Impact factor: 2.850

Review 5.  Targeting B cells and antibody in transplantation.

Authors:  M R Clatworthy
Journal:  Am J Transplant       Date:  2011-06-10       Impact factor: 8.086

Review 6.  Sensitized renal transplant recipients: current protocols and future directions.

Authors:  James Gloor; Mark D Stegall
Journal:  Nat Rev Nephrol       Date:  2010-03-16       Impact factor: 28.314

7.  Effect of high-dose intravenous immunoglobulin on anti-HLA antibodies in sensitized kidney transplant candidates.

Authors:  Vinay Nair; Deirdre Sawinski; Enver Akalin; Rex Friedlander; Zeynep Ebcioglu; Vinita Sehgal; Rajani Dinavahi; Rafael Khaim; Scott Ames; Susan Lerner; Barbara Murphy; Jonathan S Bromberg; Peter S Heeger; Bernd Schröppel
Journal:  Clin Transplant       Date:  2012 May-Jun       Impact factor: 2.863

Review 8.  Experimental models of vasculitis and glomerulonephritis induced by antineutrophil cytoplasmic autoantibodies.

Authors:  J Charles Jennette; Hong Xiao; Ronald Falk; Adil Mohamad Hussein Gasim
Journal:  Contrib Nephrol       Date:  2011-01-20       Impact factor: 1.580

9.  Intravenous immunoglobulin for antibody-mediated keratolimbal allograft rejection.

Authors:  Victoria Squissato; Jeffrey Schiff; Clara C Chan
Journal:  BMJ Case Rep       Date:  2015-06-25

Review 10.  The generation and maintenance of serum alloantibody.

Authors:  M R Clatworthy; M Espeli; N Torpey; K G C Smith
Journal:  Curr Opin Immunol       Date:  2010-10       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.